Form 4: Zimmer Biomet Director Hagemann Reports Acquisition of Phantom Stock Units

Director Robert Hagemann reports acquiring phantom stock units in Zimmer Biomet Holdings, Inc. under the Deferred Compensation Plan for Non-Employee Directors.

Summary

• Robert Hagemann, a director of Zimmer Biomet Holdings, Inc., filed a Form 4 on April 2, 2025, reporting a transaction on March 31, 2025.
• The transaction involved the acquisition of 299.974 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The price of the derivative security is $0.
• The phantom stock units were accrued at a price of $112.51 per unit.
• These units will be settled in cash in five annual installments after Hagemann's service as a director ends.
• Hagemann directly owns 29,597.688 shares of common stock, including 63.054 phantom stock units accrued on January 31, 2025, through dividend reinvestment.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing an insider transaction, which carries a neutral sentiment.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company.
• The Deferred Compensation Plan allows for tax-deferred accumulation of wealth.

Future Outlook

The phantom stock units will be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company directors.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding director compensation and alignment of interests.

Key Dates

Keywords

Form 4, Zimmer Biomet, Hagemann, Phantom Stock Units, Director, Deferred Compensation Plan, Beneficial Ownership